Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. develops and commercializes graphene-enabled and advanced material technologies through platforms that include ZenGUARD™, Albany Graphite and Triera. Company developments center on ZenGUARD™ enhanced air filters and related regulatory classification, commercialization pathways and HVAC supply-chain opportunities.
Recurring updates also cover the Albany Graphite Project in Ontario, including technical studies, environmental and social baseline work, market analysis and high-purity graphite positioning for nuclear, defence, battery and industrial markets. Triera Biosciences updates focus on aptamer discovery, biosensor enablement, machine-learning classification and infectious-disease applications, alongside material agreements, capital-structure disclosure, governance matters and operating results.
Zentek Ltd. (NASDAQ:ZTEK) has secured an initial order of ZenGUARD™ coated masks from Mark's, a leading Canadian retailer. This partnership will enhance the product's visibility in over 380 stores across Canada and online, offering a high-quality, Canadian-made option for safety wear. ZenGUARD™ provides 99% antimicrobial activity, including against COVID-19, positioning Zentek as a key player in innovative healthcare solutions. The collaboration may also open doors for future applications of Zentek's nanotechnologies.
Zentek Ltd. (Nasdaq:ZTEK; TSX-V:ZEN) has engaged The Benchmark Company as a strategic financial advisor for potential transactions related to its Albany Graphite Deposit in Northern Ontario. The engagement comes amid growing interest in North American sourced battery-grade graphite. CEO Greg Fenton emphasized the importance of Benchmark's expertise in evaluating commercial opportunities. Zentek owns 100% of the Albany Deposit and continues to focus on developing healthcare solutions, including the antimicrobial coating ZenGUARD.
Zentek Ltd. (NASDAQ:ZTEK) has announced a definitive supply agreement with EkoMed Global Inc. to enhance personal protective equipment (PPE) using Zentek's proprietary ZenGUARD™ coating. This collaboration aims to initially treat surgical masks with the ZenGUARD™ technology, known for its 99% antimicrobial activity. EkoMed's capabilities include the production of over 1.2 billion masks annually, positioning Zentek for greater market access and potential innovations in PPE. CEO Greg Fenton highlighted the strategic importance of this partnership for expanding ZenGUARD™ sales globally.
Zentek Ltd. (NASDAQ: ZTEK), a Canadian intellectual property development firm, has announced the successful completion of Phase 1 testing for its ZenGUARD™-coated HVAC filters. Following this, the company will advance to Phase 2 testing under its Innovation Solutions Canada contract. Phase 1 confirmed the coating's effectiveness in reducing airborne organisms while maintaining airflow. The upcoming Phase 2 aims to further validate the coating's safety and efficacy in a classroom setting. This progression is significant for indoor air quality initiatives and commercialization efforts.
Zentek Ltd. (NASDAQ: ZTEK) has partnered with FTI Consulting to aid its U.S. market expansion, focusing on the regulatory approval process for its ZenGUARD™ nanotechnology. This partnership aims to navigate the complicated federal regulations and potentially launch ZenGUARD™, which boasts 99% antimicrobial activity, including against COVID-19. This announcement follows Zentek's recent debut on the NASDAQ, enhancing its strategy to commercialize innovative healthcare solutions.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN) has filed a provisional patent for a Graphene Oxide-Metal-Organic Framework (GO-MOF) aimed at enhancing fire retardant products. The company emphasizes environmentally friendly components and efficient production methods. Initial tests for the GO-MOF in fire retardants have shown promising results, indicating its potential application in various coatings and in creating lightweight, fire-resistant plastics for electric vehicles. Zentek's innovative approach enhances its value proposition in health and safety.
Zentek Ltd. (Nasdaq:ZTEK) announced the publication of its international patent application for ZenGUARD technology by the World Intellectual Property Office. This milestone reflects the company’s progress from scientific breakthrough to commercialization. The ZenGUARD technology, which exhibits 99% antimicrobial activity, including effectiveness against COVID-19, aims to enhance revenue potential through commercial opportunities. Zentek is scaling production in its Guelph facility and actively pursuing market opportunities for ZenGUARD, particularly in transmission prevention with coated masks.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN; OTC PINK:ZENYF) announced its SEC Form 40-F registration statement is effective, and its common stock will start trading on the Nasdaq Capital Market under the symbol ZTEK on March 22, 2022. CEO Greg Fenton stated this milestone will enhance liquidity, attract U.S. investors, and increase visibility. Zentek focuses on next-gen healthcare solutions, including ZenGUARD™, an antimicrobial coating with 99% efficacy against COVID-19, and an exclusive partnership for rapid pathogen detection technology.